MURA muraloncology.com Final Profit

Corporate emblem and logo of muraloncology.com (MURA)

The profit dynamics of Mural Oncology plc (MURA) are illustrated on this GURU.Markets chart, where the indicator has reached the level of -0.12, supported by a liquid balance and the success of the drug nemvalekin. Risks are minimized through the development of modified cytokines to combat kidney cancer. An innovative pipeline and patent protection create significant barriers for competitors, strengthening the issuer's market position.

MURA (Mural Bio) Net Profit history from 02/21/2024 to 12/20/2025

Analytical breakdowns and data insights for company muraloncology.com (MURA)

- stock value and consensus price forecast:
Market Price Mural Oncology|MURA - Price Target Chart
- market capitalization data:
Market Value MURA|MURA - Real Price to Acquire Entire Company
- business book valuation details:
Accounting Value of a Share Mural Oncology|MURA - Book Capitalization|Market Cap to Net Assets Ratio muraloncology.com|MURA - Cumulative Company Assets
- debt and solvency information:
Total Debt to Capital Mural Oncology plc|MURA - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital Mural Oncology|MURA - Company Aggregate Debts|Debts to Book Value MURA|MURA - Company Long-Term Debt|Company Current Liabilities Mural Oncology|Quick Ratio muraloncology.com
- net income and valuation multiples indicators:
MURA - Company Net Income
Fundamental valuation:MURA Mural Bio
Manufactured product of Mural Oncology PLC

The scaling efficiency of the Mural Oncology plc (MURA) clinical portfolio is determined by the ability to optimize immunotherapy development costs while maintaining growth rates. This metric measures the difference between operating income and total expenses in real-time, allowing investors to assess the burn rate and margin sustainability, as reflected in the company's current net result.

Main competitors

Company Net Income BeiGene Oncology (ONC)|Company Net Income Halozyme Therapeutics|RVMD: Final Profit|Net Income AAPG (Ascentage Pharma)|CGON (CG Oncology Inc) - Final Profit|Net Profit URGN (UroGen)|BCAX - Net Income|PSNL: Net Income|ERAS - Net Profit|Delcath Systems (DCTH) - Company Net Income|Y-mAbs Therapeutics Inc - Final Profit|AURA (Aura Bio) - Net Profit|Company Net Income Candel CADL|Company Net Income Accuray Incorporated (ARAY)|Net Income sellaslifesciences.com SLS|Actuate Therapeutics - Net Income|Net Profit Citius Oncology Inc. CTOR|HURA - Company Net Income|Final Profit TARA (Protara Tx)|FATE: Net Profit|Aadi Bioscience (WHWK) - Net Profit|Company Net Income TScan Therapeutics Inc|Company Net Income CSBR|Net Income XBIT (XBiotech Inc.)|CVM (cel-sci.com) - Final Profit|Company Net Income OS Therapies Incorporated OSTX|Radiopharm Theranostics Ltd (RADX) - Company Net Income|ARTV - Company Net Income|ANL (Adlai Nortye Ltd.) - Company Profit|VERU: Net Profit|Net Income Tempest Therapeutics Corp|Company Net Income Xilio Therapeutics Inc|Company Net Income Enochian BioSciences RENB|Company Net Income Kairos Pharma Ltd (KAPA)|Company Net Income OKUR (onkuretherapeutics.com)|Company Net Income CytoMed Therapeutics Limited GDTC|Curis Inc. (CRIS) - Company Net Income|Apollomics Corp - Net Profit|Annual Net Income tharimmune.com (THAR)|ADVB (advanbiomed.com) - Net Income|Company Net Income Genprex Inc. (GNPX)|Net Income CLDI|SBFM: Final Profit|Company Net Income Xenetic Biosciences (XBIO)|SLRX: Profit After Tax|Company Net Income Purple Biotech Ltd. PPBT|American Oncology Network Inc - Company Net Income|BeOne Medicines - Net Profit|Checkpoint Therapeutics Inc (CKPT) - Net Income|Elevation Oncology, Inc. (ELEV) - Company Net Income|Net Income iCAD|Net Income IKNA|Net Profit Notable Labs Ltd|Company Net Income Viracta Therapeutics (VIRX)|MOR (MorphoSys Corporation) - Final Profit|Net Profit NAYA (NAYA Biosciences)|Net Profit ascentage.com AAPGV